Drug Index

EYLEA

Generic: AFLIBERCEPT

Review priority: STANDARD Marketing status: Prescription

Route: INJECTION
Class: General Medications
Safety profile: routine
Latest regulatory update: 10 Oct 2024, 12:00 am (UTC)

Structured Monograph

Approval overview EYLEA is listed in Drugs@FDA under application 125387 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient AFLIBERCEPT Form and strength INJECTABLE; INJECTION - 40MG/ML Sponsor REGENERON PHARMACEUTICALS Submission history Latest submission status date: 2024-10-10 00:00:00. Submission type: SUPPL.